Abstract
To evaluate the efficacy and safety of rivaroxaban versus low molecular weight heparin for the prevention of deep vein thrombosis after hip arthroplasty, 30 patients with primary unilateral hip arthroplasty in the Yijishan Hospital of Wannan Medical College between January 2017 and December 2018 were selected and randomly divided into the rivaroxaban group and the low molecular weight heparin group. Treatments started 6 h after replacement, the patients in the rivaroxaban group received rivaroxaban 10 mg/d for 5 w and the another group received low molecular weight heparin 4100 U/d for 2 w. Results indicated that full course of rivaroxaban demonstrated distinct efficacy with safety in preventing deep vein thrombosis after hip arthroplasty.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
